Amyloidosis Forum: Scientific Workshop on Considerations for Novel Endpoint Development in AL Amyloidosis

ARC and the FDA will be hosting a virtual Scientific Workshop as part of the Amyloidosis Forum work on Novel Endpoint Development in AL amyloidosis.

Following the most recent Amyloidosis Forum held on October 15, 2020, several different organ-specific working groups have formed through the ARC/FDA public private partnership to facilitate the development of a composite or multidomain endpoint for AL amyloidosis.  This Amyloidosis Forum meeting will bring together each of these organ-specific working groups along with independent and regulatory statisticians to discuss the output of each working group and potential components to a composite or multidomain endpoint in AL amyloidosis.

The Amyloidosis Forum is a Public Private Partnership between the Amyloidosis Research Consortium (ARC) and the Food and Drug Administration (FDA). The Amyloidosis Forum is focused on accelerating drug development in AL amyloidosis.